Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perspective: What is the over/under for revenue exceeding $5 million for the month of March?
How long can you hold your breath?
$ALYI has priced itself with its $100 million RevoltToken transfer ownership plan. Isn't $IQST the most likely partner/ suitor with the managerial competence to profitably bring the bike to market? Why should $IQST limit its interest in the project to $200/ battery on a product whose current ownership has an extremely insecure path for realizing profitable production?
$ALYI has priced itself with its $100 million RevoltToken transfer ownership plan. Isn't $IQST the most likely partner/ suitor with the managerial competence to profitably bring the bike to market? Why should $IQST limit its interest in the project to $200/ battery on a product whose current ownership has an extremely insecure path for realizing profitable production?
I wasn't wr, wr, wro, wro...
December 7th, 2020 PR did in fact make march 18th a nearly drop dead date for publishing study findings. Now should I weigh with emphasis how the late data may de-prioritize placement at ASCO in June as an indicator of increased risk? Will short traders prop the stock price up to play bagholder games?
Probably far left field thinking, but doesn't ASCO late abstract submission criteria explicitly exclude TLD? https://meetings.asco.org/am/late-breaking-data-submission-guidelines
It would be shameful, regardless of study results, if $CVM's multikine study did not factor into ASCO this June.
So if I formed a developmental stage pharmaceutical company founded on the notion that a patented retinoic compound that has crossed the blood brain barrier & produced neurogenesis by regulating N-acetylaspartate balance in rat models & then funded my research with share selling loan agreements requiring me to contract a Transfer Agent earning commissions based upon the daily volume of shares exchanged, at what point in future time of me not bringing a product to market would you call my company a "scam"?
I am creating an analogy between patents for biologicals & the value & risks associated with business relationships in underdeveloped markets that are made and exposed as deficient by the whims of geopolitical tensions & economic gamesmanship.
The word "scam" is being tossed around too freely. Most business ideas fail to gain traction. This does not mean that their paper/debt trading or business failure delegitimizes & criminalizes the endeavor. If I wanted, I could incorporate a personal newspaper, establish credit for it, obtain a DUNS number by soliciting DUNS & Bradstreet, & then sell shares in a desperate quest to make a media empire (all while earning a meager living from the activities).
The word "scam" is being tossed around too freely. Most business ideas gain traction. This does not mean the paper/debt trading or business failure delegitimizes & criminalizes those endeavors. If I wanted, I could incorporate a personal newspaper, establish credit for it, obtain a DUNS number by soliciting DUNS & Bradstreet, & then sell shares in a desperate quest to make a media empire (all while earning a meager living from the activities).
If Dabrowski, on the other hand, has been accumulating a fortune of Bitcoin, all hands on deck.
$ALYI management's ambitious EV planning is realizable. Clearly, they are intelligent enough to understand that they must produce Audited financials & increase their accountability to shareholders & cryptocurrency owners by making themselves & the company fully subject to the broadest & finest details of regulatory oversight.
I expect the current CEO to fall on his sword implementing an increase to Authorized Shares to make sure the financials are audited. And, then, I expect the new CEO to follow up with a reverse split (to defend share price).
I expect the trading price of IQST to exceed $2 by the end of the month & for their 10k (which will be released at that time) to pave the way for a rapid climb to $5 by the end of April. As they have stated a goal of continuing mergers & acquisitions enabled by the establishment of capital formation (dilutive), I'd expect the IQST share price to be above $10 this summer & sway with the tides of efficient growth thereafter.
$IQST is experiencing rapid revenue Growth, it has no debt, it is streamlining its subsidiaries, it has marginal Outstanding Shares, & it is determined to uplist (could have joined OTCQB last summer) & that is likely to be on the nasdaq which generally requires Share price to be $3 (but their is a $2 provision). Also, IQST has tweeted that they will make an announcement about uplisting this week & have messaged their Ambassadors group on Facebook that News is also imminent.
I'll bet that these are all demonstration trades originating from the original 30000 sold yesterday by the Revolt Token Deployer. FWIW, I expect $ALYI trading to fully indicate uncertainties until institutional investors & other venture capitalists are motivated by sector heavy weights better attuned to its analytics & their information needs.
Those who haven't established their $IQST position already still have a brief opportunity to nurse local wounds & seed future hopes.
If Elon Musk / $TSLA were to get involved with the RVLT token, one would think he or they would, in part, time such investment to advance the purchasing power of potential new EV consumers. ALYI management & investors should caution their roller coastered expectations with patience.
the new MM behemoth is borrowing from the 4.3 million shares available to raid the market.
1. a) I'd feel much better about $IQST's reconstituted Russell MicroCap (RM) inclusion if its application for uplisting to the Nasdaq, as a testament to Market Efficiency, was made on March 1 because 4 to 6 weeks of processing applies to much pressure upon RM deadlines.
2. Be very careful with price forecasts from stock promoters who are only relying upon 8 weeks of data and who are not weighting seasonal (calendar) effects (especially when they let slip their 20% profit regret)
Apparently Elon Musk doesn't like stable coins.
Or did they say pegged to the dollar? Something like that Elon Musk (@elonmusk)
20, 2021Or did they say pegged to the dollar? Something like that …
— Elon Musk (@elonmusk) February 20, 2021
I am dismayed by the lack of imaginative belief of some board posters when the 1000% run up of IQST's share price since late December 2020 is considered as an exponentiating factor for the tightening of share structure's impact on its continuing bull run (despite likely naked trading by MMs).
BTW, if you are dependent upon buy the hype & sell the news trading insights of self-styled trading gurus, then know that you are being played solely for the benefit of their portfolio gains (especially in light of the fact that IQST is in the habit of stacking its news releases for sequential release.
Behaving as confident & long-run minded shareholders will help advantage IQST in identifying & capturing enterprises which offer its subsidiaries new synergies & greater revenue. If no one sells shares until IQST is $26 it will be too expensive for some time to attract the institutional investors looking to finance expansion & diversification. It is after these dilutive SPAs occur that skilled investors keenly average up their historic purchase price on saddle for the continuing long ride up.
In short, exiting too soon entails troubling dilution & risky mergers. Holding way too long, on the other hand, will stifle growth.
If an equity firm is taking over, they may force a continued sell off and then take ALYI private before spinning out anew with an IPO. A lot of uncertainty has creeped into the forecast picture of when value multiples will occur again.
If the RevoltToken is to be valued at $1 and as 1 share of ALYI, shouldn't 1 share of ALYI be => $1 by the time of the ICO?
Nasdaq Capital Market: Financial and Liquidity Requirements
+ 6 week application process
https://listingcenter.nasdaq.com/assets/initialguide.pdf
See Requirements
* Currently traded companies qualifying solely under the Market Value Standard must meet the $50 million Market Value of Listed
Securities and the applicable bid price requirement for 90 consecutive trading days before applying.
** Effective August 2019 Nasdaq’s initial listing criteria were revised to exclude securities subject to resale restrictions for any reason from
the calculation of publicly held shares, market value of publicly held shares and round lot shareholders. In addition, the round lot
shareholder requirements were revised to also require that at least half of the minimum required number of round lot holders must each
hold unrestricted securities with a minimum value of $2,500.
*** To qualify under the closing price alternative, a company must have: (i) average annual revenues of $6 million for three years, or (ii)
net tangible assets of $5 million, or (iii) net tangible assets of $2 million and a 3 year operating history, in addition to satisfying the other
financial and liquidity requirements listed above.
Nasdaq Global Market: Financial and Liquidity Requirements |
+ 6 week application process
https://listingcenter.nasdaq.com/assets/initialguide.pdf
See requirements
*Currently traded companies qualifying solely under the Market Value Standard must meet the $75 million Market Value of Listed
Securities and the $4 bid price requirement for 90 consecutive trading days before applying.
** Effective August 2019 Nasdaq’s initial listing criteria were revised to exclude securities subject to resale restrictions for any reason from
the calculation of publicly held shares, market value of publicly held shares and round lot shareholders. In addition, the round lot
shareholder requirements were revised to also require that at least half of the minimum required number of round lot holders must each
hold unrestricted securities with a minimum value of $2,500.
In addition to the above requirements, if the security is trading in the U.S. over-the-counter market as of the date of application, the
security must have a minimum average daily trading volume of 2,000 shares (including trading volume of the underlying security on the
primary market with respect to an ADR), over the 30 trading day period prior to listing, with trading occurring on more than half of those
30 days, unless such security is listed on the Exchange in connection with a firm commitment underwritten public offering of at least $4
million.
If you are suggesting that a post uplisting leap to mid cap revenues is in the offing, I am inclined to agree. It is my belief that IQST will face an adjustment period until development of its most lucrative earnings catalyst is fully commercialized.
If I am putting numbers on my expectations, then
1) a quick ride above $7 pre-listing
2) Trading in the $5-9 range while it makes necessary business investments post-listing
3) Above $15 after its most important project is fully commercialized in 4Q 2021 & 1Q 2022
Shouldn't we expect the share price for a small cap to have its best performance & uplisted trading range established while it is a standout performer on the OTC rather than after it joins a major exchange where it will just be another face in a crowd of excellently managed & performing companies? If so, then sharp vertical movement to that plateau should occur any day now.
YAWN!!!
YAWN!!!
Electric bikes built by novices do not use super lightweight high efficiency batteries calibrated for use by sophisticated diagnostic tools & security failsafe software protecting proprietary interests of owners, users, customers, & energy services.
Whether full investigation bracketed [tld] is good or bad, my expectations & calendar are looking past placeholder indications.
Checked on my portfolio this morning & discovered my good till cancel sell order at 30.75 was executed without news. I find the idea that wallstreetbets was responsible for my realized returns extremely dubious. Seems far more likely that hedge funds are using the news cycle to price in their expectations for trial results.
GLTA
If the RevoltToken is intended to provide working capital for production of Alternet's electric vehicle fleet, then it is essential that it trades on a tight float with strong support from venture capital.
Emerging details about collaborative partners have significantly strengthened Alternet's viability, but until investment capital is plainly available for use the exponentially skyrocketing potential of share price will have dime store range limits. An approach to $2.00 by july 2021 & uplisting are definitely in play. A well played RS, at that point, could add additional multiples with global manufacturing expansions
Every gain that I've ever enjoyed from trading in and out of CVM has been wiped out. I embarrassingly exited with 40% losses. I am sure to return when its discounted price & action suggests opportunity exists for me to make up the losses. I am in savings mode for that opportunity and its attendant tax payment expectations for April 2019.
I am persuaded that Alan French Jr. is negligence incarnate. If he has any role in the Cel-Sci v Pharmanet litigation, Navigators Specialty Insurance is in trouble.
InVentiv Health Consulting files trade secrets suit against former employees
https://www.bizjournals.com/triangle/news/2018/06/26/now-part-of-syneos-inventiv-health-consulting.html?ana=yahoo&yptr=yahoo
InVentiv Health Consulting – now part of Syneos Health (Nasdaq: SYNH) following INC Research’s 2017 mega-merger with inVentiv Health – has filed a lawsuit in federal court against former employees, citing trade secret misappropriation and other allegations
The complaint states that while still employed at inVentiv, former managing director Alan French Jr. and a former employee of a top client co-founded at the end of 2015 a competing company: Essex, Vermont-based Equitas Life Sciences.
“During this time, French also secretly transitioned client work … from inVentiv to Equitas, and performed the work through Equitas,” the complaint states, including work for two top clients worth “several million dollars in revenue” from 2013 to 2016. “To cover his tracks and explain away corresponding declining revenues, French told his superiors at inVentiv that the clients’ need for consulting services had simply diminished.”
The complaint claims that in the first half of 2016, the bulk of French’s team members resigned from inVentiv, citing personal reasons like family, health and education, and “none told inVentiv that they planned to go work with French at Equitas.”
“That is, however, precisely what happened; the former employees left inVentiv to work for Equitas and secretly transitioned two of inVentiv’s top clients to Equitas using inVentiv’s confidential customer information,” the complaint states, adding that, “just two days before his resignation, French accessed myriad confidential documents using his inVentiv computer and inserted a thumb drive into the computer immediately afterwards, presumably so that he could take and use inVentiv’s confidential information on behalf of Equitas.”
InVentiv alleges that the “coordinated effort” violates the defendants’ employment agreements with inVentiv, along with both state and federal trade secrets and unfair competition law. According to inVentiv Health Consulting’s complaint, the company is seeking “injunctive relief to protect its trade secrets [and] damages flowing from defendants’ misconduct.”
French said in an email that, “it is Equitas’s policy not to comment on pending litigation.” Syneos also declined to comment.
It is not unreasonable to believe that the currently realized Market Cap reflects a 1:1 cash potential expectation for all warrants being exercised because of the impending Arbitration decision.
Because a positive arbitration decision will liberate other CVM IND activities, its market cap ratio, notwithstanding its peer trend, should change in accordance with their network expanding potentiations.
Realized cash burn from the NDA & new INDs can then be weighed as 1:1 offsets of MC
Edit: If your 1:1 market cap assessment of Price to Expected Cash holds water then wouldn't 25 million shares (as exercised through $4.50) produce a market cap of $112.5 million & thus ruin your math?
I am a bit more optimistic about what Price: Cash {implied earnings} for a late stage immunotherapy could be averaged as by the market.
I'd only project a $Billion+ MC on ~35 million (as exercised through $19.75) shares if CVM is awarded more than $150 million (P: cash {implied earnings} would then be 4.25: 1). {4.25: 1 also roughly fits the peer group trend}
I don't discount exuberance but expect it to be averaged out by Effective declarations on the exercise of warrants
If your 1:1 market cap assessment of Price to Expected Cash holds water then wouldn't 25 million shares (as exercised through $4.50) produce a market cap of $125 million & thus ruin your math?
I am a bit more optimistic about what Price: Cash {implied earnings} for a late stage immunotherapy could be averaged as by the market.
I'd only project a $Billion+ MC on ~35 million (as exercised through $19.75) shares if CVM is awarded more than $150 million (P: cash {implied earnings} would then be 4.25: 1). {4.25: 1 also roughly fits the peer group trend}
I don't discount exuberance but expect it to be averaged out by Effective declarations on the exercise of warrants
Closing arguments in the arbitration suit against the former CRO were concluded on April 25, 2018, and the arbitrator indicated he would render his judgement in the matter within 60 days of the conclusion of closing arguments. The arbitrator has now requested until Friday June 29, 2018 to make his Final Award.
S-1 indicated Warrants to be exercised obtain for CVM about $8,150.000
Change in Outstanding Common Shares of 1,746,304 from 5-24 to 6-22
600,000 of which went to ErgoMed seems to indicate that 1,146,303
must have been CVM-WS exercised warrants for $2,000,000
$8,150,000 + 2,000,000 = $10,150,000
If there is to be an appeal of ARB by PharmaNet/Inventiv/Syneos then the $10,150,000 should meet cash burn expectations for 6 months if LEAPS or Perianal trials are advanced to their Next development phase.
More than $50,000,000 in warrants do not yet have an S-1 indicated declaration of exercise.